Drugs / 18F-DCFBC
18F-DCFBC
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01417182 | Sep 2010 → Sep 2014 | prostate cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01815515 | Mar 2013 → Jul 2015 | metastatic prostate carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 1/2 | NCT01496157 | Sep 2012 → Jan 2015 | prostate cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | (18)F-DCFBC | “We previously demonstrated the ability to detect metastatic prostate cancer using N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-(18)F-fluorobenzyl-L-cysteine ((18)F-DCFBC), a...” PMID 26069305 ↗ Jun 2015 |
| Known as | DCFBC F-18 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1232667 ↗ |
| Known as | N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-(18)F-fluorobenzyl-L-cysteine | “We previously demonstrated the ability to detect metastatic prostate cancer using N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-(18)F-fluorobenzyl-L-cysteine ((18)F-DCFBC), a...” PMID 26069305 ↗ Jun 2015 |
| Action | Inhibit | “a radiolabeled urea-based small molecule inhibitor of prostate-specific membrane antigen (PSMA)” NCT01496157 ↗ |
| Modality | Diagnostic / imaging agent | “radiopharmaceutical which is radiolabeled with a fluorine-18 positron emitter for PET imaging” NCT01417182 ↗ |
| Route | Intravenous | “injected once into the IV line by slow push IV push” NCT01417182 ↗ |